# XIENCE 28 USA Study

Study · id `cardio:ct-nct03815175` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03815175](<https://clinicaltrials.gov/study/NCT03815175>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03815175

Browse, organ or system: Heart; Brain  
Browse, condition area: Coronary and vascular disease; Stroke  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1605 participants.

## Technical summary

Registry record NCT03815175. Allocation not applicable; no masking; primary purpose treatment. Start 2019-02-25 (actual); primary completion 2020-08-14 (actual). Results posted on 2021-12-14.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 1605 participants (enrolled count; ClinicalTrials.gov record NCT03815175, source copy `cardio:ctgov-nct03815175-2022-05-03`, retrieved 2026-10-26)
- Started: 2019-02-25 (actual) (ClinicalTrials.gov record NCT03815175, source copy `cardio:ctgov-nct03815175-2022-05-03`, retrieved 2026-10-26)
- Primary completion: 2020-08-14 (actual) (ClinicalTrials.gov record NCT03815175, source copy `cardio:ctgov-nct03815175-2022-05-03`, retrieved 2026-10-26)
- Completion: 2021-02-04 (actual) (ClinicalTrials.gov record NCT03815175, source copy `cardio:ctgov-nct03815175-2022-05-03`, retrieved 2026-10-26)
- Results first posted: 2021-12-14 (ClinicalTrials.gov record NCT03815175, source copy `cardio:ctgov-nct03815175-2022-05-03`, retrieved 2026-10-26)
- Countries: United States; Austria; Belgium; Canada; China; Germany; Hong Kong SAR China; Italy; Netherlands; Portugal; Singapore; Spain; Switzerland; Taiwan; United Kingdom (ClinicalTrials.gov record NCT03815175, source copy `cardio:ctgov-nct03815175-2022-05-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03815175-2022-05-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: XIENCE 28 USA Study
- Condition: Bleeding Disorder
- Condition: Ischemic Stroke
- Condition: Hemorrhagic Stroke
- Condition: Hematological Diseases
- Condition: Thrombocytopenia
- Condition: Coagulation Disorder
- Condition: Anemia
- Condition: Renal Insufficiency
- Condition: Coronary Artery Disease
- Intervention (Device): XIENCE
- Intervention (Drug): DAPT (aspirin and/or P2Y12 receptor inhibitor)
- Lead sponsor: Abbott Medical Devices
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Abbott (`cardio:abbott`)

## Provenance

Content hash: a2b2d285621b6b023a41652578d2aadc699a7e295841c93afe515b07402fe9af
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
